Grifols (GRFS) Other Accumulated Expenses (2009 - 2021)
Grifols (GRFS) posted Other Accumulated Expenses of $1.1 billion for Q3 2020, down 2.41% quarter-over-quarter from $1.1 billion in Q1 2020, and down 0.9% year-on-year from $1.1 billion in Q4 2019.
Grifols (GRFS) Other Accumulated Expenses (2009 - 2021) Analysis & Trends
Grifols (GRFS) has reported Other Accumulated Expenses for 11 consecutive years, with $1.1 billion the latest figure, recorded in Q3 2020.
- Other Accumulated Expenses for Q3 2020 came in at $1.1 billion, down 0.9% year-over-year; the trailing twelve-month figure through Sep 2020 was $1.1 billion (down 0.9% YoY), and the FY2019 annual result was $1.1 billion, down 0.52% from the prior year.
- Other Accumulated Expenses was $1.1 billion for Q3 2020 at Grifols, down from $1.1 billion in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $1.1 billion in Q4 2018 and troughed at $125.4 million in Q2 2016.
- Average Other Accumulated Expenses over 5 years is $712.0 million, with a median of $975.7 million recorded in 2018.
- The widest YoY moves for Other Accumulated Expenses: up 90076.21% in 2016, down 11.36% in 2016.
- Over 5 years, Other Accumulated Expenses stood at $151.4 million in 2016, then surged by 540.14% to $968.9 million in 2017, then advanced by 15.44% to $1.1 billion in 2018, then dropped by 0.52% to $1.1 billion in 2019, then decreased by 2.94% to $1.1 billion in 2020.
- Per Business Quant data, the three most recent Other Accumulated Expenses figures were $1.1 billion in Q3 2020, $1.1 billion in Q1 2020, and $1.1 billion in Q4 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Grifols | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 250.84 Mn |
| Dec 31, 2020 | 182.61 Mn |
| Sep 30, 2020 | 1.08 Bn |
| Mar 31, 2020 | 1.11 Bn |
| Dec 31, 2019 | 1.11 Bn |
| Sep 30, 2019 | 1.09 Bn |
| Dec 31, 2018 | 1.12 Bn |
| Sep 30, 2018 | 975.69 Mn |
| Jun 30, 2018 | 165.40 Mn |
| Mar 31, 2018 | 1.09 Bn |
| Dec 31, 2017 | 968.93 Mn |
| Jun 30, 2017 | 141.55 Mn |
| Dec 31, 2016 | 151.36 Mn |
| Sep 30, 2016 | 133.26 Mn |
| Jun 30, 2016 | 125.37 Mn |
| Dec 31, 2015 | 147.61 Mn |
| Sep 30, 2015 | 150.33 Mn |
| Jun 30, 2015 | 139,030.09 |
| Mar 31, 2015 | 138.08 Mn |
| Dec 31, 2014 | 184.83 Mn |